Invention Grant
- Patent Title: Soluble AXL receptor tyrosine kinase in the diagnosis of cancer
-
Application No.: US15126661Application Date: 2015-03-18
-
Publication No.: US10823737B2Publication Date: 2020-11-03
- Inventor: Wolfgang Mikulits , Patrick Reichl
- Applicant: Medizinische Universität Wien
- Applicant Address: AT Vienna
- Assignee: Medizinische Universität Wien
- Current Assignee: Medizinische Universität Wien
- Current Assignee Address: AT Vienna
- Agency: Parker Highlander PLLC
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@5185afef
- International Application: PCT/EP2015/055724 WO 20150318
- International Announcement: WO2015/140231 WO 20150924
- Main IPC: G01N33/574
- IPC: G01N33/574
Abstract:
The present invention relates to a method for assessing whether a patient suffers from cancer, such as hepatocellular carcinoma, or is prone to suffering from cancer, such as hepatocellular carcinoma, wherein said method comprises determining the amount of soluble AXL in a sample from the patient. The patient is assessed to suffer from cancer or to be prone to suffering from cancer when the amount of soluble AXL is increased in comparison to a control. The present invention relates to the use of soluble AXL for assessing whether a patient suffers from cancer, such as hepatocellular carcinoma, or is prone to suffering from cancer, such as hepatocellular carcinoma. Also a kit for use in the methods of the present invention is provided.
Public/Granted literature
- US20170146540A1 SOLUBLE AXL RECEPTOR TYROSINE KINASE IN THE DIAGNOSIS OF CANCER Public/Granted day:2017-05-25
Information query
IPC分类:
